Saccharomyces boulardii in maintenance treatment of Crohn's disease

M. Guslandi, G. Mezzi, M. Sorghi, P. A. Testoni

Research output: Contribution to journalArticle


The possible role of Saccharomyces boulardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn's disease has been evaluated. Thirty-two patients with Crohn's disease in clinical remission (CDAI <150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent. Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn's disease. However, in view of the product's cost, further controlled studies are needed to confirm these preliminary data.

Original languageEnglish
Pages (from-to)1462-1464
Number of pages3
JournalDigestive Diseases and Sciences
Issue number7
Publication statusPublished - 2000


  • Crohn's disease
  • Mesalamine
  • Probiotics
  • Relapses
  • Saccharomyces boulardii

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Saccharomyces boulardii in maintenance treatment of Crohn's disease'. Together they form a unique fingerprint.

Cite this